MedTrace Logo

Omega 3 FA Supplements as Augmentation in the Treatment of Depression

NCT01803711 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2017-12-27

Study results available
· View outcomes & findings →

Summary

To assess the efficacy of Omega 3 Fatty acid (Omega 3 FA) augmentation of desvenlafaxine (DVS) compared to placebo augmentation of DVS when used to treat depression and anxiety symptoms in patients with select medical conditions (cancer, cardiovascular diseases and diabetes).

Conditions

Interventions

DRUG

Desvenlafaxine

DIETARY_SUPPLEMENT

Omega 3 Fatty acids

DRUG

Placebo (for Omega 3 fatty acid supplement)

Sponsors & Collaborators

  • UConn Health

    lead OTHER

Principal Investigators

  • Jayesh Kamath, MD PhD · UConn Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2016-06-30
Completion
2016-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01803711 on ClinicalTrials.gov